← Back to Search

Anti-metabolites

Pemetrexed Disodium for Non-Small Cell Lung Cancer

Phase 2

Waitlist Available

Led By Stefan Grant

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial is testing whether pemetrexed disodium is effective in treating patients with stage IV non-small cell lung cancer who have a lower performance status.

Eligible Conditions

Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Quality of Life (QOL), Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and QLQ-Lung Cancer 13-item (LC13)

Time to Tumor Progression

Secondary outcome measures

Incidence of Hematologic Toxicity, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

Overall Survival

Response Rate

Side effects data

From 2015 Phase 2 trial • 22 Patients • NCT01001910

36%

Hematologic

14%

Non-Hematologic

100%

80%

60%

40%

20%

Study treatment Arm

Treatment (Pemetrexed Disodium, Carboplatin)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (pemetrexed disodium)Experimental Treatment3 Interventions

Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Quality-of-Life Assessment and Laboratory Biomarker Analysis.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pemetrexed Disodium

2015

Completed Phase 2

~280

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,660 Previous Clinical Trials

40,924,256 Total Patients Enrolled

Wake Forest University Health SciencesLead Sponsor

1,241 Previous Clinical Trials

1,004,221 Total Patients Enrolled

Stefan GrantPrincipal InvestigatorWake Forest University Health Sciences

2 Previous Clinical Trials

54 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

For what purpose is this medication commonly prescribed?

"Pemetrexed Disodium is most commonly used as an ovarian cancer treatment, but it can also be administered to patients suffering from unresectable thymoma, locally advanced nonsquamous non-small cell lung cancer, and mesotheliomas."

Answered by AI

Is Pemetrexed Disodium a new medication?

"There are a total of 235 studies underway that are researching Pemetrexed Disodium. Of those, 92 are in Phase 3. The many studies for Pemetrexed Disodium have their origins in Winston-Salem, North carolina, but there are 19361 locations running studies for this treatment."

Answered by AI

Has Pemetrexed Disodium been cleared by the FDA?

"While Phase 2 trials provide limited data on a medication's efficacy, there is at least some evidence of Pemetrexed Disodium's safety, so it received a score of 2."

Answered by AI

What is the total number of people enrolled in this clinical trial?

"No, this particular research project is not enrolling patients at this time. The listing for this trial was first published on May 1st, 2015 and was most recently updated on June 9th, 2022. If you are interested in similar studies, there are 1949 clinical trials actively recruiting patients with lung cancer and 235 Pemetrexed Disodium trials searching for participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3

2015. "Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02426658.